The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.

The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.

The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.

The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.

Provided are a donor-acceptor type compound having a novel structure and its use. An enamine compound represented by general formula (1) ##STR00001##
(in the formula: R.sup.1 represents an electron-withdrawing group; A represents a divalent aromatic hydrocarbon group which may contain a substituent, a divalent aromatic heterocyclic group which may contain a substituent or a divalent unsaturated aliphatic hydrocarbon group which may contain a substituent; R.sup.2 represents a hydrogen atom or a hydrocarbon group which may contain a substituent; R.sup.3 and R.sup.4 are the same or different from each other and represent an aromatic hydrocarbon group which may contain a substituent or an aromatic heterocyclic group which may contain a substituent, or R.sup.3 and R.sup.4 together form an optionally substituted bicyclic aromatic heterocyclic group containing two or more nitrogen atoms or a nitrogen atom and an oxygen atom or a sulfur atom, or a tricyclic aromatic heterocyclic group which may contain a substituent; and R.sup.2 and A, or R.sup.2 and R.sup.3 may together form a cyclic structure).

Provided are a donor-acceptor type compound having a novel structure and its use. An enamine compound represented by general formula (1) ##STR00001##
(in the formula: R.sup.1 represents an electron-withdrawing group; A represents a divalent aromatic hydrocarbon group which may contain a substituent, a divalent aromatic heterocyclic group which may contain a substituent or a divalent unsaturated aliphatic hydrocarbon group which may contain a substituent; R.sup.2 represents a hydrogen atom or a hydrocarbon group which may contain a substituent; R.sup.3 and R.sup.4 are the same or different from each other and represent an aromatic hydrocarbon group which may contain a substituent or an aromatic heterocyclic group which may contain a substituent, or R.sup.3 and R.sup.4 together form an optionally substituted bicyclic aromatic heterocyclic group containing two or more nitrogen atoms or a nitrogen atom and an oxygen atom or a sulfur atom, or a tricyclic aromatic heterocyclic group which may contain a substituent; and R.sup.2 and A, or R.sup.2 and R.sup.3 may together form a cyclic structure).

The present disclosure provides borate or aluminate activators comprising cations having linear alkyl groups, catalyst systems comprising, and methods for polymerizing olefins using such activators. Specifically, the present disclosure provides activator compounds represented by Formula: [R.sup.1R.sup.2R.sup.3EH].sub.d.sup.+[M.sup.k+Q.sub.n].sup.d−, wherein: E is nitrogen or phosphorous; d is 1, 2 or 3; k is 1, 2, or 3; n is 1, 2, 3, 4, 5, or 6; n−k=d; R.sup.1 is C.sub.1-C.sub.20 linear alkyl group; each of R.sup.2 and R.sup.3 is a C.sub.1-C.sub.40 linear alkyl group, a meta- and/or para-substituted phenyl group, an alkoxy group, a silyl group, a halogen, or a halogen containing group, wherein R.sup.1+R.sup.2+R.sup.3≥15 carbon atoms; M is an element selected from group 13, typically B or Al; and each Q is independently a hydride, bridged or unbridged dialkylamido, halide, alkoxide, aryloxide, hydrocarbyl, substituted hydrocarbyl, halocarbyl, substituted halocarbyl, or halosubstituted-hydrocarbyl radical, provided that when Q is a fluorophenyl group, then R.sup.2 is not a C.sub.1-C.sub.40 linear alkyl group.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Antidegradant composition comprising a first compound of Formula I:

##STR00001##

and a second antidegradant that is not the compound of Formula I; and rubber composition comprising the antidegradant composition. The rubber composition has good resistance to appearance discoloration while maintaining the mechanical and anti-aging properties, thus, are suitable for making the entire tire or as part of the rubber matrix.